Bioverativ (BIVV) Receives News Impact Rating of 0.20
Media headlines about Bioverativ (NASDAQ:BIVV) have been trending somewhat positive on Thursday, according to Accern. Accern ranks the sentiment of media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Bioverativ earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 45.7873573637654 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the headlines that may have effected Accern Sentiment Analysis’s rankings:
- Bioverativ Inc (BIVV) Receives Average Rating of “Hold” from Analysts (americanbankingnews.com)
- Zoetis Inc. (ZTS) registers a price change of 0.90% while Bioverativ Inc. (BIVV) finishes with a flow of -0.81% – Stocks Gallery (stocksgallery.com)
- Healthcare Stock is Neither Hold nor sell: Bioverativ Inc. (BIVV) – Street Observer (press release) (streetobserver.com)
- Consolidated Edison, Inc. (ED) Hits a New 52-Week High (fishinghd.com)
- Bioverativ : and Bicycle Therapeutics to develop new haemophilia and sickle cell disease treatments (4-traders.com)
A number of brokerages have issued reports on BIVV. Zacks Investment Research raised shares of Bioverativ from a “sell” rating to a “hold” rating in a research note on Thursday, August 24th. Evercore ISI began coverage on shares of Bioverativ in a research note on Wednesday, August 16th. They issued an “in-line” rating and a $58.00 price objective on the stock. Jefferies Group LLC reaffirmed a “buy” rating and issued a $70.00 price objective (up from $67.00) on shares of Bioverativ in a research note on Wednesday, August 9th. Cowen and Company reissued a “buy” rating and set a $80.00 price target on shares of Bioverativ in a research report on Friday, August 4th. Finally, William Blair began coverage on shares of Bioverativ in a research report on Wednesday, June 28th. They set a “market perform” rating on the stock. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $60.43.
Bioverativ (BIVV) opened at 56.46 on Thursday. The company has a market capitalization of $6.11 billion and a PE ratio of 13.42. Bioverativ has a 12 month low of $41.88 and a 12 month high of $57.82. The stock’s 50 day moving average is $56.88 and its 200-day moving average is $53.59.
Bioverativ (NASDAQ:BIVV) last announced its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported $0.88 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.71 by $0.17. The business had revenue of $289.10 million during the quarter, compared to analyst estimates of $269.00 million. During the same quarter last year, the company posted $0.59 earnings per share. The company’s revenue was up 37.5% compared to the same quarter last year. On average, analysts expect that Bioverativ will post $2.92 EPS for the current year.
In other news, insider Diantha Duvall sold 818 shares of the stock in a transaction on Wednesday, June 28th. The shares were sold at an average price of $60.47, for a total transaction of $49,464.46. Following the completion of the sale, the insider now directly owns 2,128 shares in the company, valued at $128,680.16. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Louis J. Paglia acquired 2,000 shares of the firm’s stock in a transaction dated Monday, August 7th. The shares were purchased at an average price of $59.70 per share, with a total value of $119,400.00. Following the completion of the transaction, the director now owns 5,056 shares of the company’s stock, valued at $301,843.20. The disclosure for this purchase can be found here.
Bioverativ Company Profile
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ Inc and related companies with MarketBeat.com's FREE daily email newsletter.